Long-term Outcomes Associated With Juvenile-onset Mycosis Fungoides and Lymphomatoid Papulosis
Part of paid clinical trials in Houston, Texas.
- Sponsor
- M.D. Anderson Cancer Center
- Study ID
- NCT06207812
- Status
- Recruiting
Conditions
- Lymphomatoid Papulosis
- Mycosis Fungoides
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Study Details
To follow up with all our participants with juvenile-onset mycosis fungoides, check on their status, and ask them or their parents about long term outcomes associated with their condition.
Key Dates
- Start date
- Jan 19, 2024
- Status verified
- Jan 2026
- Primary completion
- Jan 12, 2028
- Completion
- Jan 12, 2028
Study Design
- Enrollment
- 100 participants (estimated)
Primary Outcome Measure
Safety and adverse events (AEs) [ Time Frame: Through study completion; an average of 1 year ]
Central Contacts
- Julia Dai, MD(713) 515-7961
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| MD Anderson Cancer Center | Houston | Texas | 77030 | Julia Dai, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Houston, TX
By research site
Related Studies
- ID Of Prognostic Factors In Mycosis Fungoides/Sezary SyndromeRecruiting · Stanford University · Duarte, California
- Ultra Low Dose Radiation Therapy in Treating Patients With Mycosis FungoidesPHASE2 · Recruiting · M.D. Anderson Cancer Center · Houston, Texas
- Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin LymphomaPHASE1 · Recruiting · SciTech Development, Inc. · Scottsdale, Arizona
- Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis FungoidesPHASE2 · Recruiting · M.D. Anderson Cancer Center · Houston, Texas